Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01522495 · ClinicalTrials.gov registry record · NA
Pilot Study to Determine Percent Tissue Perfusion and Cellular Viability Using SPY Imaging
A NA study, sponsored by Georgetown University.
- Completed
- Registry status
- NA
- Development phase
- 31
- Enrollment target
NCT01522495: Completed NA study, sponsored by Georgetown University.
NCT01522495 is a NA study that has completed, run by Georgetown University. The registered enrollment target is 31 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01522495, a NA study, has completed, sponsored by Georgetown University.
- COMPLETED
- Registry status
- NA
- Development phase
- 31 participants
- Enrollment target
Study Summary
Little is known about chronic wound microenvironments, especially in peripheral vascular disease (PVD) and diabetic patients. At the demarcation line, the percentage of viable cells and tissue is unclear. A means to determine cell viability, particularly discerning an apoptotic or necrotic cell pathway would indicate where the line of demarcation should be drawn. The information generated would better predict clinical outcome using SPY Imaging. Cellular studies are needed to successfully confirm a clear line of demarcation to eliminate surgeon subjectivity.
Primary Outcome
Determine percent cellular viability (vs. apoptotic/dead) of cells at demarcation line
Interventions
- DEVICE SPY Imaging, ICG dye (0.2 - 0.5 mg/kg)
- DEVICE SPY Imaging
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2013-04 |
| Est. Completion | 2019-12 |
| Phase | NA |
What the finished NCT01522495 record still lists
NCT01522495 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 31 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 2 interventions - of which SPY Imaging, ICG dye (0.2 - 0.5 mg/kg) is the first listed.
NCT01522495 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01522495 about?
NCT01522495 is a clinical study titled "Pilot Study to Determine Percent Tissue Perfusion and Cellular Viability Using SPY Imaging". Little is known about chronic wound microenvironments, especially in peripheral vascular disease (PVD) and diabetic patients. At the demarcation line, the percentage of viable cells and tissue is unclear. A means to determine cell viability, particularly discerning an apoptotic or necrotic cell path...
What is the current status of trial NCT01522495?
This trial is currently completed. It is a NA study. The enrollment target is 31 participants. The study started on 2013-04. Estimated completion is 2019-12.
What interventions are being tested in trial NCT01522495?
The interventions under investigation include: SPY Imaging, ICG dye (0.2 - 0.5 mg/kg) (DEVICE), SPY Imaging (DEVICE).
Who is sponsoring clinical trial NCT01522495?
This trial is sponsored by Georgetown University, which has 227 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01522495's enrollment target sits among peer trials
31 1592nd of 2000 higher than 408 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02932618 · 31 participants · Phase 3
A Study of Recombinant Von Willebrand Factor (rVWF) With or Without ADVATE in Children With Severe Von Willebrand Disease (VWD)
- NCT03482297 · 31 participants · Phase 1
Automated Abdominal Binder for Orthostatic Hypotension
- NCT04016389 · 31 participants · NA
FIGO 2018 Stage IB2 Cervical Cancer Treated With Neoadjuvant Chemotherapy Followed by Fertility Sparing Surgery
- NCT04211675 · 31 participants · Phase 1
NK Cells Infusions With Irinotecan, Temozolomide, and Dinutuximab
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia